NCT05262309View on ClinicalTrials.gov

An Open-label, Randomized, Parallel-arm Study Investigating the Efficacy and Safety of Intravenous Administration of Pamrevlumab Versus Standard of Care in Patients With COVID-19

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

May 12, 2020

Primary Completion Date

January 1, 2022

Study Completion Date

January 1, 2022

Conditions
COVID-19 Respiratory InfectionCOVID-19 PneumoniaCovid19
Interventions
DRUG

Pamrevlumab

"Pamrevlumab dosing, 30 mg/kg IV, will be administered at day 1, day 7 and day 14.~Based on Investigator's decision, treatment may be continued every 3 weeks after day 14, up to 11 weeks."

Trial Locations (1)

00168

Fondazione Policlinico Agostino Gemelli IRCCS, Rome

All Listed Sponsors
lead

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER

NCT05262309 - An Open-label, Randomized, Parallel-arm Study Investigating the Efficacy and Safety of Intravenous Administration of Pamrevlumab Versus Standard of Care in Patients With COVID-19 | Biotech Hunter | Biotech Hunter